Brief: Protalix Biotherapeutics Issues Statement Regarding Security Situation In Israel
Oct 9 (Reuters) - Protalix Biotherapeutics Inc PBDA.F :
* PROTALIX BIOTHERAPEUTICS ISSUES STATEMENT REGARDING
SECURITY
SITUATION IN ISRAEL
* PROTALIX BIOTHERAPEUTICS INC - OPERATIONS HAVE NOT BEEN
ADVERSELY AFFECTED BY SECURITY SITUATION IN ISRAEL
* PROTALIX BIOTHERAPEUTICS INC - DO NOT ANTICIPATE ANY
DISRUPTION
TO SUPPLY OF ELFABRIO OR ELELYSO
Source text for Eikon: ID:nPn2FVLbja
Further company coverage: PBDA.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Protalix BioTherapeutics
See all newsIsrael's Protalix Q2 revenue rises on Elfabrio sales, reiterates 2026 outlook
Israel's Protalix Q1 revenue surges on Chiesi milestone
Brief: Protalix BioTherapeutics Q1 EPS USD 0.23
Brief: Protalix Biotherapeutics Reports Fiscal Year 2025 Financial And Business Results
Brief: EU Approves Four‑week Dosing Option For Chiesi and Protalix’s Elfabrio